Seven low-mass ions in pretreatment serum as potential predictive markers of the chemoradiotherapy response of rectal cancer
- Authors
- Roh, Kangsan; Yeo, Seung-Gu; Yoo, Byong Chul; Kim, Kyung-Hee; Kim, Sun Young; Kim, Min-Jeong
- Issue Date
- Sep-2016
- Publisher
- Lippincott Williams & Wilkins Ltd.
- Keywords
- chemoradiotherapy; low-mass ions; metabolite; rectal neoplasms
- Citation
- Anti-Cancer Drugs, v.27, no.8, pp 787 - 793
- Pages
- 7
- Journal Title
- Anti-Cancer Drugs
- Volume
- 27
- Number
- 8
- Start Page
- 787
- End Page
- 793
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/8819
- DOI
- 10.1097/CAD.0000000000000391
- ISSN
- 0959-4973
1473-5741
- Abstract
- Preoperative chemoradiotherapy (CRT) is generally performed for locally advanced rectal cancer (LARC, cStage 2 or 3) to improve local disease control and patient survival. The pathological tumor response to CRT is a surrogate marker that is associated with oncological outcome. Thus, markers that predict the response to CRT would be valuable for individualizing treatment for LARC patients. The current study used metabolomics-based approaches to identify molecular markers that predict the response to CRT. Seventy-six patients with LARC who received pelvic radiotherapy and concurrent chemotherapy using tegafururacil and leucovorin were enrolled. Radical surgery was performed 6-8 weeks after the completion of CRT. The postsurgical pathological CRT response was evaluated using the ypStage or tumor regression grade. Profiling patterns of low-mass ions (LMIs) in the pretreatment sera were obtained from all patients using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Our previously developed two-step algorithms, which showed a powerful diagnostic capability during colorectal cancer screening, were then used to screen for meaningful LMIs with discriminatory power. One combination consisting of seven LMIs was identified, whose discriminatory score separated a good CRT response (ypStage 0-1) from a poor CRT response (ypStage 3-4) successfully. However, each individual LMI alone showed insignificant discriminatory power. This finding suggests that analysis of the LMIs in pretreatment serum could serve as a predictive marker of the CRT response in patients with LARC. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Radiation Oncology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.